ID: MRFR/MED/5303-HCR | January 2023 | Region: Global | 90 Pages
Leukapheresis Products Market is expected to hold a value of about USD 19.2 Million with CAGR of 7.7% during the forecast period.
$19.2 million
7.7%
North America
2022-2030
Leukapheresis Products Market Overview Leukapheresis products market is anticipated that the market held a market value of USD 19.2 million in 2017 and is projected to grow at a CAGR of 7.7% over the forecast period. Leukapheresis is a blood therapy that removes aberrant white blood cells (WBCs). Leukemia can be treated using leukapheresis, or it can be utilized as the initial stage in CAR T-cell therapy. The rising number of blood donors, the rising prevalence of leukemia, and the demand for leukapheresis products in clinical trials are all expected to drive the market forward. The high cost of therapeutic leukapheresis, a scarcity of qualified experts, and strict donor recruitment requirements, on the other hand, may limit market expansion over the projection period. Despite its therapeutic potential, leukapheresis is currently a rare treatment option, especially for hyperleukocytosis leukemia. Therapeutic leukapheresis in the treatment of pediatric patients, on the other hand, is becoming a hot topic among industry participants. This is primarily due to the negative effects and hazards of traditional treatments for children, such as chemotherapy. Leukapheresis can be used to treat or remove excess WBCs in children with lymphoma, as well as to collect stem cells from children for other cancer patients. The possibilities and benefits of leukapheresis in this application make it a market focus, especially as only a few hospitals in both developed and emerging economies presently provide leukapheresis treatment for children.
Segmentation:
The leukapheresis products market has been segmented into type, application, and end user. On the basis of type, the market has been segmented into leukapheresis devices and leukapheresis disposables. The leukapheresis devices segment has been segmented into apheresis devices, leukapheresis column & cell separators, and leukoreduction filters.
The market, on the basis of application, has been segmented into research applications and therapeutic applications.
On the basis of end user, the market has been segmented into blood component providers and blood centers, hospitals and transfusion centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The leukapheresis products market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European leukapheresis products market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The leukapheresis products market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The leukapheresis products market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players:
Haemonetics, Terumo BCT, Asahi Kasei Medical, STEMCELL Technologies, Macopharma, HemaCare Corporation, Caltag Medsystem, ALLCells, LLC, ZENBIO, Fresenius Kabi, PPA Research Group, StemExpress and others are some of the key players in the leukapheresis products market.
Regional Market Summary: Global Leukapheresis Products Market Share (%), by Region, 2017
Source: America’s Blood Centers, White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the leukapheresis products market owing to the growing number of blood donations, rising incidence and prevalence of leukaemia and growing demand for leukopaks in clinical research. According to the America’s Blood Centers, more than 15 million pints of blood are transfused in the US each year.
Europe is expected to hold the second largest position in the leukapheresis products market. The market growth in this region is attributed to the increasing prevalence of leukemia and well-developed healthcare sector in the region. According to the Cancer Research UK, about 9,900 new cases of leukaemia were reported in UK in 2015.
The leukapheresis products market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increase in regenerative medicine research in the region, growth in the number of clinical trials for CAR-T therapy, and the increasing presence of major multinational pharma and biotech companies, and improvement in healthcare access.
The Middle East & Africa has the lowest share of the leukapheresis products market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.Recent Development
Leukapheresis Products Market, by Type
Leukapheresis Products Market, by Application
Leukapheresis Products Market, by End User
Leukapheresis Products Market, by Region
Leukapheresis Products Market, by Key Players
Intended Audience
Report Attribute/Metric | Details |
---|---|
Market Size |
|
CAGR | 7.7% (2017-2023) |
Base Year | 2019 |
Forecast Period | 2020-2027 |
Historical Data | 2018 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type, Application and End user |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Haemonetics, Terumo BCT, Asahi Kasei Medical, STEMCELL Technologies, Macopharma, HemaCare Corporation, Caltag Medsystem, ALLCells, LLC, ZENBIO, Fresenius Kabi, PPA Research Group, StemExpress and others |
Key Market Opportunities | New product launches and R&D Amongst major key Players |
Key Market Drivers |
|
The leukapheresis products market is projected to grow at a 7.7% CAGR between 2018-2023.
The Americas is projected to command the largest share in the leukapheresis products market.
Rising prevalence of leukemia is boosting market growth.
High cost may limit market growth.
Different strategies used by market players to create a dominance in the leukapheresis products market include product launches, collaborations, strategic alliances, and others.